Shen Lian Biomedical(SH:688098) Ge Long Hui·2025-10-26 07:41Core Viewpoint - The company announced a strategic investment in its associate company, Yangzhou Shizhiyuan Biotechnology Co., Ltd., aiming to enhance its innovative drug business through acquiring controlling interest [1] Group 1: Investment Details - The company's wholly-owned subsidiary, Shanghai Bentiang Biotechnology Co., Ltd., holds a 20.48% stake in Yangzhou Shizhiyuan [1] - In late 2024, Yangzhou Shizhiyuan plans to initiate financing, with the company and Central Fu (Feidong) Investment Fund Partnership intending to invest CNY 60 million each [1] - The investment by Shanghai Bentiang has been completed, while the Central Fu Fund has finalized its establishment and due diligence processes [1] Group 2: Control Acquisition - A framework agreement has been signed among the company, Yangzhou Shizhiyuan, and its controlling shareholders for the acquisition of controlling interest [1] - Following the new round of investment, Yangzhou Shizhiyuan will become a controlled subsidiary of the company, included in the consolidated financial statements [1]